Stockwatch: Magic, distraction and denial
This article was originally published in Scrip
Executive Summary
If you hadn't noticed, the biotechnology sector is in full reverse. IPOs and secondary offerings have been cancelled and the share prices of new IPOs like Ophthotech, finished the week down over 14% against an NASDAQ Biotech Index that was itself down only about 2%.